Kromek targets £60m revenue with 30% EBITDA margin in growth plan

Published 18/06/2025, 07:22
 Kromek targets £60m revenue with 30% EBITDA margin in growth plan

LONDON - Kromek Group plc (AIM:LON:KMK), a detection technology company, revealed plans to scale its business to achieve revenues exceeding £60 million with a 30% EBITDA margin as part of its growth strategy presented at its capital markets day on Wednesday.

The company, which specializes in advanced imaging and CBRN (Chemical, Biological, Radiological and Nuclear) detection markets, also announced it will begin reporting revenue by division starting with its upcoming financial results for the year ended April 30, 2025.

Historical division revenue figures disclosed at the event showed CBRN Detection generated £10.4 million in fiscal 2024, up from £8.6 million in 2023, while Advanced Imaging contributed £9.0 million, compared to £8.7 million the previous year.

In a May 8 trading update, Kromek stated it expects to report fiscal 2025 revenue of at least £26 million, representing year-on-year growth of at least 34%, attributed to its partnership with Siemens (ETR:SIEGn) Healthineers.

The capital markets day, held at Cavendish Capital Markets’ London offices, provided institutional investors and analysts an opportunity to meet the leadership team and hear from industry representatives. No additional material information beyond the previously announced growth targets and historical divisional breakdown was disclosed.

The company will make presentation materials and a recording available on its website following the event. Kromek also plans to host a separate online Q&A session for retail investors on June 25.

Based in County Durham, UK, Kromek develops radiation detection and bio-detection technology solutions with manufacturing operations in both the UK and US, according to the press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.